Reviewing Beigene (ONC) & Its Peers

Beigene (NASDAQ:ONC) is one of 1,075 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Beigene to related companies based on the strength of its analyst recommendations, earnings, risk, dividends, institutional ownership, profitability and valuation.

Risk and Volatility

Beigene has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Beigene’s rivals have a beta of 3.84, meaning that their average share price is 284% more volatile than the S&P 500.

Earnings & Valuation

This table compares Beigene and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beigene	$3.81 billion	-$881.71 million	-41.17
Beigene Competitors	$9.90 billion	$136.37 million	-5.95

Beigene’s rivals have higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

48.5% of Beigene shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 7.4% of Beigene shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Beigene and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beigene	-25.94%	-25.12%	-14.95%
Beigene Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Recommendations

This is a breakdown of current recommendations for Beigene and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beigene	0	0	4	0	3.00
Beigene Competitors	8513	22411	50620	1366	2.54

Beigene currently has a consensus price target of $316.71, suggesting a potential upside of 25.30%. As a group, “Pharmaceutical preparations” companies have a potential upside of 231.85%. Given Beigene’s rivals higher probable upside, analysts clearly believe Beigene has less favorable growth aspects than its rivals.

Summary

Beigene rivals beat Beigene on 7 of the 13 factors compared.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.